Clinical impact of fluvoxamine-mediated long QTU syndrome

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2012, Vol.68 (1), p.109-111
Hauptverfasser:	Nia, Amir M., Dahlem, Kristina M., Gassanov, Natig, Hungerbühler, Hansjörg, Fuhr, Uwe, Er, Fikret
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Anxiety Agents - adverse effects Anti-Anxiety Agents - therapeutic use Biomedical and Life Sciences Biomedicine Cognition Disorders - complications Epilepsy - complications ERG1 Potassium Channel Ether-A-Go-Go Potassium Channels - antagonists & inhibitors Female Fluvoxamine - adverse effects Fluvoxamine - therapeutic use Humans Letter to the Editors Long QT Syndrome - chemically induced Long QT Syndrome - physiopathology Long QT Syndrome - therapy Middle Aged Multiple Sclerosis - complications Obsessive-Compulsive Disorder - complications Obsessive-Compulsive Disorder - drug therapy Pharmacology/Toxicology Potassium Channel Blockers - adverse effects Potassium Channel Blockers - therapeutic use Schizophrenia - complications Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!